Cargando…
FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways
Objective: Endometrial cancer (EC) is the second most common gynecological cancer worldwide. Myometrial invasion (MI) is a key event in EC dissemination. This study aimed to evaluate FXYD5/dysadherin (FXYD5/Dys) expression in EC tissue and uterine aspirate (UA) biopsies and to assess molecular/funct...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908519/ https://www.ncbi.nlm.nih.gov/pubmed/31867269 http://dx.doi.org/10.3389/fonc.2019.01306 |
_version_ | 1783478740927381504 |
---|---|
author | Besso, María José Rosso, Marina Lapyckyj, Lara Moiola, Cristian Pablo Matos, María Laura Mercogliano, María Florencia Schillaci, Roxana Reventos, Jaume Colas, Eva Gil-Moreno, Antonio Wernicke, Alejandra Orti, Roberto Vazquez-Levin, Mónica Hebe |
author_facet | Besso, María José Rosso, Marina Lapyckyj, Lara Moiola, Cristian Pablo Matos, María Laura Mercogliano, María Florencia Schillaci, Roxana Reventos, Jaume Colas, Eva Gil-Moreno, Antonio Wernicke, Alejandra Orti, Roberto Vazquez-Levin, Mónica Hebe |
author_sort | Besso, María José |
collection | PubMed |
description | Objective: Endometrial cancer (EC) is the second most common gynecological cancer worldwide. Myometrial invasion (MI) is a key event in EC dissemination. This study aimed to evaluate FXYD5/dysadherin (FXYD5/Dys) expression in EC tissue and uterine aspirate (UA) biopsies and to assess molecular/functional changes associated with its expression in cellular models. Methods: FXYD5/Dys messenger RNA (mRNA) levels were determined in EC tissue and UA biopsies. FXYD5/Dys expression was evaluated in EC RNAseq data from The Cancer Genome Atlas (TCGA) and GENEVESTIGATOR tools. FXYD5/Dys impact on E-cadherin expression and cell behavior was assessed in EC Hec1a cells treated with transforming growth factor (TGF)-β1, stably transfected with ETV5, and transiently transfected with FXYD5/Dys small interfering RNA (siRNA) or pcDNA3-FXYD5/Dys plasmid. Results: FXYD5/Dys was associated with EC aggressiveness, finding high mRNA levels in tumors depicting MI > 50%, Grade 3, and intermediate/high risk of recurrence. FXYD5/Dys was highly expressed at the tumor invasive front compared to the superficial area. Most results were recapitulated in UA biopsies. FXYD5/Dys modulation in Hec1a cells altered cell migration/adhesion and E-cadherin expression. TGF-β1 treatment of Hec1a cells induced FXYD5/Dys expression. TCGA-UCEC RNAseq analysis revealed a positive correlation between FXYD5/Dys, TGF-β1, and plasminogen activator inhibitor (PAI)-1 mRNA levels. FXYD5/Dys induced nuclear factor (NF)-κB pathway activation in Hec1a cells. FXYD5/Dys mRNA levels positively correlated with transcriptional activation of NF-κB p65-regulated genes. Survival analysis revealed patient segregation into low- and high-risk groups, the latter depicting the highest FXYD5/Dys, PAI-1, tumor necrosis factor (TNF)-α, and TGF-β1 mRNA levels and shorter survival rates. Conclusion: FXYD5/Dys is a novel biomarker of EC progression related to TGF-β1 and NF-κB pathways that collectively promote tumor dissemination and result in poor patient prognosis. |
format | Online Article Text |
id | pubmed-6908519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69085192019-12-20 FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways Besso, María José Rosso, Marina Lapyckyj, Lara Moiola, Cristian Pablo Matos, María Laura Mercogliano, María Florencia Schillaci, Roxana Reventos, Jaume Colas, Eva Gil-Moreno, Antonio Wernicke, Alejandra Orti, Roberto Vazquez-Levin, Mónica Hebe Front Oncol Oncology Objective: Endometrial cancer (EC) is the second most common gynecological cancer worldwide. Myometrial invasion (MI) is a key event in EC dissemination. This study aimed to evaluate FXYD5/dysadherin (FXYD5/Dys) expression in EC tissue and uterine aspirate (UA) biopsies and to assess molecular/functional changes associated with its expression in cellular models. Methods: FXYD5/Dys messenger RNA (mRNA) levels were determined in EC tissue and UA biopsies. FXYD5/Dys expression was evaluated in EC RNAseq data from The Cancer Genome Atlas (TCGA) and GENEVESTIGATOR tools. FXYD5/Dys impact on E-cadherin expression and cell behavior was assessed in EC Hec1a cells treated with transforming growth factor (TGF)-β1, stably transfected with ETV5, and transiently transfected with FXYD5/Dys small interfering RNA (siRNA) or pcDNA3-FXYD5/Dys plasmid. Results: FXYD5/Dys was associated with EC aggressiveness, finding high mRNA levels in tumors depicting MI > 50%, Grade 3, and intermediate/high risk of recurrence. FXYD5/Dys was highly expressed at the tumor invasive front compared to the superficial area. Most results were recapitulated in UA biopsies. FXYD5/Dys modulation in Hec1a cells altered cell migration/adhesion and E-cadherin expression. TGF-β1 treatment of Hec1a cells induced FXYD5/Dys expression. TCGA-UCEC RNAseq analysis revealed a positive correlation between FXYD5/Dys, TGF-β1, and plasminogen activator inhibitor (PAI)-1 mRNA levels. FXYD5/Dys induced nuclear factor (NF)-κB pathway activation in Hec1a cells. FXYD5/Dys mRNA levels positively correlated with transcriptional activation of NF-κB p65-regulated genes. Survival analysis revealed patient segregation into low- and high-risk groups, the latter depicting the highest FXYD5/Dys, PAI-1, tumor necrosis factor (TNF)-α, and TGF-β1 mRNA levels and shorter survival rates. Conclusion: FXYD5/Dys is a novel biomarker of EC progression related to TGF-β1 and NF-κB pathways that collectively promote tumor dissemination and result in poor patient prognosis. Frontiers Media S.A. 2019-12-06 /pmc/articles/PMC6908519/ /pubmed/31867269 http://dx.doi.org/10.3389/fonc.2019.01306 Text en Copyright © 2019 Besso, Rosso, Lapyckyj, Moiola, Matos, Mercogliano, Schillaci, Reventos, Colas, Gil-Moreno, Wernicke, Orti and Vazquez-Levin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Besso, María José Rosso, Marina Lapyckyj, Lara Moiola, Cristian Pablo Matos, María Laura Mercogliano, María Florencia Schillaci, Roxana Reventos, Jaume Colas, Eva Gil-Moreno, Antonio Wernicke, Alejandra Orti, Roberto Vazquez-Levin, Mónica Hebe FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title | FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title_full | FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title_fullStr | FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title_full_unstemmed | FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title_short | FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways |
title_sort | fxyd5/dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with tgf-β1 and nf-κb pathways |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908519/ https://www.ncbi.nlm.nih.gov/pubmed/31867269 http://dx.doi.org/10.3389/fonc.2019.01306 |
work_keys_str_mv | AT bessomariajose fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT rossomarina fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT lapyckyjlara fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT moiolacristianpablo fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT matosmarialaura fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT mercoglianomariaflorencia fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT schillaciroxana fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT reventosjaume fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT colaseva fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT gilmorenoantonio fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT wernickealejandra fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT ortiroberto fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways AT vazquezlevinmonicahebe fxyd5dysadherinabiomarkerofendometrialcancermyometrialinvasionandaggressivenessitsrelationshipwithtgfb1andnfkbpathways |